AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUN 21 - (NewsRx Network) -- A study presented at the 14th International Congress of Cytology indicates that Ampersand Medical Corp.'s (AMPM) InPath [TM] In-Cell HPV Test [TM] has demonstrated its ability to be the first screening test capable of detecting cases in which human papillomavirus (HPV) has disregulated the host cell's central functions.
The study, conducted in the U.S., was presented by Bruce Patterson, MD, lead investigator and senior research scientist at Northwestern University, Evanston, Illinois, and a member of Ampersand's medical advisory board.
Human papillomavirus is recognized as the primary causative agent for cervical cancer. Although many women are infected with HPV, relatively few develop neoplasi . In those who do develop neoplasia, the abnormal cells overproduce specific proteins encoded fo by the virus' E6 & E7 genes.
Although current HPV screening tests identify the presence or absence of HPV through DNA detection, they don't sense the activity of HPV transforming genes. Sensing t activity may be integral in detecting and treating pre-cancerous conditions of the lower genital tract. Rather than detecting DNA, the InPath In-Cell HPV Test spots this activity, specifically through sensing the E6 & E7 messenger RNA (mRNA) expression. The test is both faster and more sensitive than HPV DNA testing.
In this study of 82 samples, InPath ...
Source: HighBeam Research, Screening Test Can Identify HPV-Disregulated Host Cell...